Clinical trial · Observational
Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes
Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Radiologically Positive Axillary Lymph Nodes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is currently debatable. It is possible that the tumor response to chemotherapy may alter the lymphatic drainage thus causing lower SLN identification rate and higher false negative rate. Further, the response of NAC can be different in each lymph nodes. It is doubtful whether SLNB can accurately predict axillary lymph node (ALN) status after NAC. The aim of this study to determine the identification rate, the false-negative rate, and the accuracy of SLNB after NAC for node positive breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| complete axillary lymph node dissection | Procedure | — | UNRESOLVED |
| Neoadjuvant chemotherapy | Drug | — | UNRESOLVED |
| positron emission tomography and ultrasonogram | Procedure | — | UNRESOLVED |
| Sentinel lymph node biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Clinically node-positive patients before NAC
- description
- Patients with clinically positive lymph node receiving neoadjuvant chemotherapy 1. Clinically negative-node after NAC 2. Clinically positive-node after NAC
- interventionNames
- Procedure: Sentinel lymph node biopsy
- Drug: Neoadjuvant chemotherapy
- Procedure: complete axillary lymph node dissection
- Procedure: positron emission tomography and ultrasonogram
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced breast cancer patients with node-positive proved in preoperative imaging study * ECOG status 0-1 Exclusion Criteria: * No previous cancer history * No previous chemotherapy history
References
Publications (0)
Data not yet available